 This is a Phase I study evaluating safety and tolerability of autologous BM-MSCs in chronic pancreatitis patients who undergo total pancreatectomy and islet autotransplantation TP-IAT. CCT-BMMSC will be infused at one of the following doses: Tier 1, 20x106 cell per patient, Tier 2, 50x106 cell per patient, and Tier 3, 100x106 cell per patient. 